This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cocklin, S.
Right arrow Articles by Chaiken, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cocklin, S.
Right arrow Articles by Chaiken, I. M.

 Previous Article  |  Next Article 

Journal of Virology, April 2007, p. 3645-3648, Vol. 81, No. 7
0022-538X/07/$08.00+0     doi:10.1128/JVI.01778-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Broad-Spectrum Anti-Human Immunodeficiency Virus (HIV) Potential of a Peptide HIV Type 1 Entry Inhibitor{triangledown}

Simon Cocklin,1* Hosahudya Gopi,1 Bianca Querido,2 Manideepthi Nimmagadda,2 Syna Kuriakose,1 Claudia Cicala,3 Sandya Ajith,1 Sabine Baxter,1 James Arthos,3 Julio Martín-García,2 and Irwin M. Chaiken1

Department of Biochemistry and Molecular Biology,1 Department of Microbiology and Immunology, Center for Molecular Virology and Neuroimmunology, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 245 N. 15th Street, Philadelphia, Pennsylvania 19102,2 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 208923

Received 16 August 2006/ Accepted 3 January 2007

The AIDS epidemic continues to spread at an alarming rate worldwide, especially in developing countries. One approach to solving this problem is the generation of anti-human immunodeficiency virus (HIV) compounds with inhibition spectra broad enough to include globally prevailing forms of the virus. We have examined the HIV type 1 (HIV-1) envelope specificity of a recently identified entry inhibitor candidate, HNG-105, using surface plasmon resonance spectroscopy and pseudovirus inhibition assays. The combined results suggest that the HNG-105 molecule may be effective across the HIV-1 subtypes, and they highlight its potential as a lead for developing therapeutic and microbicidal agents to help combat the spread of AIDS.

* Corresponding author. Mailing address: Drexel University College of Medicine, 11313 New College Building, MS #497, 245 N. 15th St., Philadelphia, PA 19102. Phone: (215) 762-3535. Fax: (215) 762-4452. E-mail: sc349{at}drexel.edu.

{triangledown} Published ahead of print on 24 January 2007.

Journal of Virology, April 2007, p. 3645-3648, Vol. 81, No. 7
0022-538X/07/$08.00+0     doi:10.1128/JVI.01778-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»